Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.47 USD
+0.09 (6.52%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.48 +0.01 (0.68%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Pacific Biosciences of California, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 632 | 773 | 1,045 | 320 | 49 |
Receivables | 37 | 19 | 24 | 17 | 15 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 57 | 50 | 25 | 14 | 13 |
Other Current Assets | 17 | 10 | 7 | 5 | 3 |
Total Current Assets | 742 | 852 | 1,101 | 356 | 81 |
Net Property & Equipment | 36 | 42 | 33 | 25 | 30 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 919 | 820 | 821 | 0 | 0 |
Deposits & Other Assets | 16 | 13 | 6 | 4 | 4 |
Total Assets | 1,746 | 1,767 | 2,007 | 414 | 148 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 16 |
Accounts Payable | 15 | 12 | 11 | 4 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 46 | 33 | 36 | 17 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 25 | 210 | 17 | 13 | 8 |
Total Current Liabilities | 95 | 263 | 72 | 39 | 49 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 6 | 2 | 25 | 2 | 2 |
Convertible Debt | 892 | 897 | 896 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 20 | 1 | 173 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,045 | 1,204 | 1,216 | 78 | 93 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,540 | 2,100 | 2,010 | 1,372 | 1,121 |
Retained Earnings | -1,839 | -1,532 | -1,218 | -1,037 | -1,066 |
Other Equity | 0 | -5 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 701 | 563 | 791 | 335 | 55 |
Total Liabilities & Shareholder's Equity | 1,746 | 1,767 | 2,007 | 414 | 148 |
Total Common Equity | 701 | 563 | 791 | 335 | 55 |
Shares Outstanding | 267.40 | 226.10 | 220.60 | 180.20 | 152.90 |
Book Value Per Share | 2.62 | 2.49 | 3.59 | 1.86 | 0.36 |
Fiscal Year End for Pacific Biosciences of California, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 632 | 768 | 830 | 875 |
Receivables | NA | 37 | 30 | 24 | 30 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 57 | 68 | 68 | 62 |
Other Current Assets | NA | 17 | 15 | 14 | 14 |
Total Current Assets | NA | 742 | 882 | 936 | 981 |
Net Property & Equipment | NA | 36 | 40 | 40 | 41 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 919 | 926 | 820 | 820 |
Deposits & Other Assets | NA | 16 | 15 | 16 | 16 |
Total Assets | NA | 1,746 | 1,898 | 1,848 | 1,896 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 15 | 16 | 17 | 17 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 46 | 35 | 27 | 19 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 25 | 124 | 219 | 220 |
Total Current Liabilities | NA | 95 | 184 | 271 | 266 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 6 | 5 | 5 | 2 |
Convertible Debt | NA | 892 | 892 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 20 | 893 | 898 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 1,045 | 1,135 | 1,206 | 1,204 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,540 | 2,522 | 2,335 | 2,314 |
Retained Earnings | NA | -1,839 | -1,757 | -1,690 | -1,620 |
Other Equity | NA | 0 | -2 | -3 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 701 | 764 | 642 | 692 |
Total Liabilities & Shareholder's Equity | NA | 1,746 | 1,898 | 1,848 | 1,896 |
Total Common Equity | 0 | 701 | 764 | 642 | 692 |
Shares Outstanding | 267.90 | 267.40 | 250.50 | 249.80 | 249.80 |
Book Value Per Share | 0.00 | 2.62 | 3.05 | 2.57 | 2.77 |